A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Condition(s):Cholangiocarcinoma Non-resectable; Cholangiocarcinoma MetastaticLast Updated:March 18, 2024Active, not recruiting